Antibody Intellectual Property Protection.
Protection for your Antibody-Based Assets.
Intellectual property (IP) rights are key considerations in the development of novel and innovative antibodies and antibody-based applications. Due to the rapidly changing nature of antibody-based technologies, it is important to co-develop patent strategies alongside any invention. To obtain patent protection, the invention must pass certain requirements including, but not limited to: novelty, inventive step/non-obviousness, and sufficiency.
As the number of antibody-based therapeutics, diagnostics and reagents continues to increase, so do patent filings corresponding to these products. As a result, IP authorities (ie. USPTO, EPO) place immense scrutiny on antibody-related patent applications during the patent prosecution process. With the help of next generation protein sequencing (NGPS) and proteomics, patent applications can be strengthened with essential data, including the sequence information of the antibody as well as its binding epitope targets and biophysical properties.
Services for Intellectual Property Protection.
We support the application process in obtaining protection for your IP. Contact us to discover how we can help with patent protection.
De Novo mAb Sequencing
Protect your mAbs and other antibody formats for therapeutic, diagnostic, research applications by obtaining their amino acid sequences and claim their composition of matter for original patent applications.
Explore REmAb
Protecting Antibodies Based on Binding Target
Characterize and specify specific antigenic epitopes for your antibodies as the scope of protection in patent applications.
Explore HDX-MS
Protecting Antibodies Based on Binding Characteristics
Strengthen patent applications with functional data by characterizing specific binding properties of your antibodies.
Explore SPR Analysis
Characterization Services
Our deep expertise working with antibodies, high throughput mass spectrometry and advanced software will give you critical insights in your antibody.
Explore Antibody Characterization Services
Application Publications.
Functional Characterization of Therapeutic Antibodies
Written by: Vanessa Yoon Calvelo, PhD Published: April 24, 2023 Contents Introduction Functions of Therapeutic [...]
Secure Full Antibody and Target IP Protection with Next Generation Protein Sequencing
Written by: Genya Gorshtein, MSc Published: April 21, 2023 Contents Introduction Target Specification for [...]
Navigating Intellectual Property Protection for Antibodies
In This Webinar, You Will Learn: Why IP is important in the development of antibody-based assets [...]
What is Peptide Mapping?
Peptide mapping is a widely used analytical technique to verify the primary structure (amino acid sequence) and characterize the chemical modifications of a protein. It analyzes peptides generated from the digestion of an isolated protein, or a protein mixture
“We’re focused on coupling cytokines with a highly engineered VHVL of an antibody. So by sequencing the antibodies with Rapid Novor we are able to pull out the CDR to graft them into our platform and test in vitro and in vivo.”
Pavel Khrimian – Co-founder and CBO, Deka Biosciences
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics